Foghorn Therapeutics Inc. FHTX
Foghorn Therapeutics Inc. (Nasdaq: FHTX) is an oncology drug developer. Its lead program, FHD-909 (LY4050784), selective SMARCA2 inhibitor, is in Phase 1 for SMARCA4-mutated cancers, primarily NSCLC. Its next catalyst on record is Pipeline (CBP, EP300, ARID1B, SMARCA2 degrader and others): Potential IND filings (up to four) (date not stated).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Pipeline (CBP, EP300, ARID1B, SMARCA2 degrader and others) — Potential IND filings (up to four) (date not stated). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| FHD-909 (LY4050784) | SMARCA4-mutated NSCLC and other solid tumors | small molecule | Phase 1 |
| Selective SMARCA2 degrader (Lilly collaboration) | SMARCA4-mutated cancers | small molecule | Pre-clinical |
| CBP degrader / EP300 / ARID1B programs | Oncology | small molecule | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.